Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial

Cesare Gridelli, Javier Carpeno, Anne-Marie C. Dingemans, Frank Griesinger, Francesco Grossi, Corey Langer, Yuichiro Ohe, Konstantinos Syrigos, Nick Thatcher, Ashis Das-Gupta, Matt Truman, Margarita Donica, Vlatka Smoljanovic, Jaafar Bennouna

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number183486
Number of pages5
JournalJAMA Oncology
Volume4
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018
Event53rd American Society of Clinical Oncology Annual Meeting 2017 - McCormick Place , Chicago, United States
Duration: 2 Jun 20176 Jun 2017
Conference number: 53

Keywords

  • 1ST-LINE TREATMENT
  • OPEN-LABEL
  • CHEMOTHERAPY

Cite this

Gridelli, C., Carpeno, J., Dingemans, A-M. C., Griesinger, F., Grossi, F., Langer, C., Ohe, Y., Syrigos, K., Thatcher, N., Das-Gupta, A., Truman, M., Donica, M., Smoljanovic, V., & Bennouna, J. (2018). Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer The AvaALL Randomized Clinical Trial. JAMA Oncology, 4(12), [183486]. https://doi.org/10.1001/jamaoncol.2018.3486